植入式迷走神经刺激后的喉科结局
该研究基于美国FDA制造商与用户设施器械经历数据库1996至2020年的数据,回顾性横断面分析发现,VNS植入后共记录12725例医源性迷走神经问题,其中喉部不良事件报告187例,为第八常见问题,包括发声改变78例和声带麻痹/瘫痪57例。作者认为结果强调术前咨询和术前喉部评估的潜在必要性。
要点
- VNS植入后喉部不良事件报告187例,为FDA收到的第八常见医源性迷走神经问题。
- 喉部不良事件包括发声改变78例和声带麻痹/瘫痪57例。
- 与喉部不良事件相关的VNS器械问题包括高阻抗15例(8.02%)、频率输送错误10例(5.35%)和电池问题11例(5.88%)。
核心结论
- 尽管文献显示几乎所有VNS器械都会出现发声改变,FDA仍收到发声改变的不良事件报告。
- 作者认为结果强调可能需要在VNS手术前改善患者咨询,以更好地设定患者对发声改变的期望并防止不必要的患者担忧。
- 作者认为声带麻痹/瘫痪的报告可能提示患者可从术前喉部评估中获益,以区分既存声带麻痹与VNS手术所致者。
研究设计与样本
- 回顾性横断面分析,查询美国FDA制造商与用户设施器械经历数据库中1996年至2020年的不良事件。
主要发现
- VNS植入后共记录12725例医源性迷走神经问题,呼吸暂停(n=395;3.1%)为最常见的患者问题。
- 共识别187例与VNS器械相关的喉部不良事件报告,为FDA收到的第八常见医源性迷走神经问题。
- 喉部不良事件包括发声改变78例报告和声带麻痹/瘫痪57例报告。
- 与喉部不良事件常相关的VNS器械问题为高阻抗(n=15,8.02%)、频率输送错误(n=10,5.35%)和电池问题(n=11,5.88%)。
- 每年喉部不良事件报告数量在2012年达到峰值,为43例。
临床怎么用
- 作者认为可能需要在VNS手术前改善患者咨询,以更好地设定患者对发声改变的期望并防止不必要的患者担忧。
- 作者认为声带麻痹/瘫痪的报告可能提示患者可从术前喉部评估中获益,以区分既存声带麻痹与VNS手术所致者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vagus nerve stimulation (VNS) devices have gained widespread acceptance for treatment of resistant epilepsy and depression. The increasing number of procedures has resulted in an increasing number of iatrogenic injuries to the vagus nerve, which can have a significant effect on vocalization and quality of life. OBJECTIVE: To determine the relative frequency of laryngeal adverse effects reported to the US Food and Drug Administration (FDA) after VNS implantation and to analyze associated VNS device problems. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional analysis queried the FDA Manufacturer and User Facility Device Experience database of adverse events in the US between 1996 and 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was the percent of adverse events reported to the FDA that included patients who received VNS with laryngeal adverse effects and the associated proportion of device problems after VNS surgery. RESULTS: A total of 12 725 iatrogenic vagus nerve issues were documented after VNS implantation, with apnea (n = 395; 3.1%) being the most common patient problem. Overall, 187 reports of laryngeal adverse effects associated with VNS devices were identified and represented the eighth most common iatrogenic vagus nerve problem reported to the FDA. Laryngeal adverse effects included 78 reports of voice alteration and 57 reports of paresis/paralysis. The VNS device problems frequently associated with laryngeal adverse effects were high impedance (n = 15, 8.02%), incorrect frequency delivery (n = 10, 5.35%), and battery problems (n = 11, 5.88%). The number of laryngeal adverse effect reports per year peaked in 2012 with 43 cases. CONCLUSIONS AND RELEVANCE: This cross-sectional study found that although the literature demonstrates that vocal changes occur with nearly all VNS devices, the FDA receives adverse event reports of voice changes. Our results emphasize a potential need to improve patient counseling prior to VNS surgery to better set patient expectations regarding vocal changes and to prevent unnecessary patient concern. In addition, reports of vocal fold paresis/paralysis potentially suggest that patients may benefit from preoperative laryngeal assessment to differentiate preexisting vocal fold paralysis from that caused by VNS surgery.
引用
- Brauer PR, Lamarre ED, Gau VL, et al. Laryngology Outcomes Following Implantable Vagus Nerve Stimulation. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36416861. doi:10.1001/jamaoto.2022.3699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。